Loading...
Market
Alumis stock price by end of 2024?
5
Resolution / Starting Odds
Above $20 • 33%
Between $10 and $20 • 33%
Below $10 • 34%
Nasdaq or major financial news outlets
Story
Alumis Prices Downsized IPO at $16 Per Share, Raises $250 Million, Valued at $902 Million
Jun 28, 2024, 04:50 AM
Alumis, an immunology biotech company, has announced the pricing of its initial public offering (IPO) at $16 per share, the low end of its marketed range of $16 to $18. The company initially planned to offer 17.65 million shares but downsized the offering to 13.125 million shares. The IPO raised $250 million, which is below its initial target of $300 million. The funds will be used to support the company's TYK2 inhibitor through phase 3 psoriasis trials and a late-stage psoriasis clinical trial. The IPO values Alumis at approximately $902 million, which is lower than the previously anticipated $1 billion valuation. The company also conducted a concurrent private placement. Notably, the IPO amount is slightly below its last VC round of $259 million. Alumis is now NasdaqListed.
View original story
Similar markets
Increased by more than 50% • 33%
Increased by 0-50% • 34%
Decreased • 33%
Less than $500 million • 33%
$500 million to $1 billion • 34%
More than $1 billion • 33%
Below $100 • 25%
$100 to $120 • 25%
$121 to $140 • 25%
Above $140 • 25%
Outperforms S&P 500 • 25%
Underperforms S&P 500 • 25%
Outperforms Dow Jones • 25%
Underperforms Dow Jones • 25%
Below $110 • 25%
$110 to $120 • 25%
$121 to $130 • 25%
Above $130 • 25%
Below $200 • 25%
$200 to $250 • 25%
$250 to $300 • 25%
Above $300 • 25%
Below HKD 100 • 25%
HKD 100 - HKD 150 • 25%
HKD 150 - HKD 200 • 25%
Above HKD 200 • 25%
Increase by more than 20% • 25%
Increase by 10%-20% • 25%
Increase by less than 10% • 25%
Decrease • 25%
Under $180 • 25%
$180-$190 • 25%
$190-$200 • 25%
Over $200 • 25%
Less than $1200 • 25%
$1200 - $1400 • 25%
$1400 - $1600 • 25%
More than $1600 • 25%